Rationale 5-Hydroxytryptamine (5-HT) transport inhibitors can attenuate the abuse-related effects of cocaine, and the mechanisms underlying this attenuation may involve activation of 5-HT2C receptors. Objectives The objective of this study was to investigate the consequences of direct and indirect pharmacological activation of 5-HT2C receptors on reinstatement of cocaine-seeking behavior induced by cocaine priming and a cocaine-paired stimulus. Methods Monkeys were trained to self-administer cocaine under a second-order schedule in which responding was maintained by i.v. cocaine injections and a cocaine-paired stimulus. Drug seeking was extinguished by replacing cocaine with vehicle and eliminating the cocaine-paired stimulus. During reinstatement tests, the animals received a priming injection of cocaine along with restoration of the cocaine-paired stimulus, but only vehicle was available for self administration. Results Pretreatment with either the 5-HT transport inhibitor fluoxetine (5.6 mg/kg) or the 5-HT2C receptor agonist Ro 60-0175 (1 mg/kg) attenuated reinstatement of drug seeking by cocaine priming. The reinstatement-attenuating effects of both drugs were reversed by the 5-HT2C receptor antagonist SB 242084 (0.03-0.56 mg/kg). Ro 60-0175 (1 mg/kg) attenuated cocaine-induced reinstatement of drug seeking regardless of whether priming injections were or were not accompanied by restoration of the cocaine-paired stimulus. Ro 60-0175 (0.56 mg/kg) was equally effective whether it was administered acutely or chronically. Finally, Ro 60-0175 (0.3-1 mg/kg) had observable behavioral effects suggestive of anxiolytic-like properties. Previous preclinical studies have shown that pharmacological inhibition of serotonin (5-Hydroxytryptamine (5-HT)) uptake resulting in increased levels of 5-HT in the synapse can attenuate the reinforcing and discriminative stimulus effects of cocaine, blunt cocaine-induced reinstatement of drug seeking, and reduce cocaine-induced increases in striatal extracellular dopamine (Spealman 1993; Howell and Byrd 1995; Czoty et al. 2002; Rüedi-Bettschen et al. 2010; Sawyer et al. 2012) . However, the neurobiological mechanisms underlying the cocaine-attenuating effects of 5-HT uptake inhibition have not been established fully.
fluoxetine administration has been attributed to changes in the level of messenger RNA (mRNA) or receptor protein, as well as to alterations in downstream signaling, associated with the 5-HT1A, 5-HT2A, and 5-HT2C receptor subtypes (Brink et al. 2004; Barbon et al. 2011; Li et al. 2012) . 5-HT2B receptors also appear to be involved in the anti-depressant actions of the 5-HT transport inhibitors, as the effects of fluoxetine and paroxetine were abolished in 5-HT2B receptor knockout mice compared to wild-type mice in a novelty-suppressed feeding test (Diaz et al. 2012) .
Only a few studies have investigated the 5-HT receptor mechanisms underlying the cocaine-modulating effects of 5-HT transport inhibitors. Rüedi-Bettschen et al. (2010) found evidence of a role for 5-HT1A receptors, showing that fluoxetine-induced attenuation of cocaine priming-induced reinstatement of drug seeking could be reversed with the 5-HT1A receptor agonist 8-OH-DPAT. Additionally, Sawyer et al. (2012) showed that concomitant with fluoxetineinduced attenuation of cocaine-induced reinstatement of drug seeking and cocaine-elicited dopamine overflow, there was evidence of fluoxetine-induced desensitization of the 5-HT2A receptor.
Recently, evidence has emerged that stimulation of 5-HT2C receptors with selective agonists can attenuate cocaine-induced elevations of dopamine within the nucleus accumbens in both rodents and monkeys, mimicking the effects of the 5-HT transport inhibitors (Navailles et al. 2008; Manvich et al. 2012a ). In rodents, 5-HT2C receptor agonists also have been shown to block several cocaine-induced behavioral effects including hyperlocomotion (Grottic et al. 2000; Filip et al. 2004; Fletcher et al. 2004; Craige and Unterwald 2013) , discriminative stimulus effects (Frankel and Cunningham 2004) , self administration (Grottic et al. 2000; Fletcher et al. 2004; , and reinstatement of drug seeking (Grottic et al. 2000; Neisewander and Acosta 2007) . Likewise, in monkeys, the 5-HT2C receptor agonists mCPP and Ro 60-0175 have been reported to reduce the behavioral stimulant, reinforcing, and relapse-inducing effects of cocaine (Manvich et al. 2012a) . Given the striking overlap in the neurochemical and behavioral effects of 5-HT2C receptor agonists compared to 5-HT transport inhibitors, as well as the fact that 5-HT2C receptors are distributed in key mesolimbic dopamine circuits (Lopez-Gimenez et al. 2001; Bubar and Cunningham 2007) , it is reasonable to investigate the contribution of this receptor subtype to the behavioral effects of 5-HT transport inhibitors.
To understand the contribution of 5-HT2C receptors to the behavioral effects of 5-HT transport inhibitors, it is first necessary to understand the role of these receptors themselves in the behavioral effects of cocaine. Therefore, we systematically evaluated the ability of the selective 5-HT2C receptor agonist Ro 60-0175 and the selective 5-HT2C antagonist SB 242084 to modulate cocaine priming-induced reinstatement of drug seeking using a nonhuman primate model of cocaine relapse (e.g., Spealman et al. 1999) . Because Ro 60-0175 has been shown to block reinstatement of drug seeking induced by contextual cues (e.g., Burbassi and Cervo 2008; Fletcher et al. 2008) , we also compared the extent to which Ro 60-0175 attenuated cocaine priming-induced reinstatement in the presence and absence of response-contingent presentations of a cocaine-paired stimulus. Additionally, because tolerance has been shown to develop rapidly with some 5-HT drugs including 5-HT2C receptor agonists (e.g., Fone et al. 1998) , we evaluated the effects of Ro 60-0175 on cocaine priminginduced reinstatement of drug seeking after both acute and chronic administrations. We also characterized the role of 5-HT2C receptors in fluoxetine-induced attenuation of cocaineinduced priming with the selective 5-HT2C antagonist SB 242084. Lastly, we evaluated the effects of Ro 60-0175 in observational studies to determine the extent to which any observed attenuation was specific to cocaine or the result of more general behavioral disruption.
Materials and methods
Subjects and surgical procedure Ten adult squirrel monkeys (Saimiri sciureus), weighing 700 to 1000 g, were studied in daily experimental sessions (Monday to Friday). Between sessions, monkeys lived in individual home cages in a climate-controlled vivarium where they had unlimited access to water and received a nutritionally balanced diet (Teklad Monkey Diet, supplemented with fresh fruit). All monkeys were maintained in accordance with the guidelines of the Committee Before beginning the present study, the monkeys were prepared with a chronic indwelling venous catheter (polyvinyl chloride, inside diameter 0.015 mm; outside diameter 0.035 mm) using the surgical procedures described by Platt et al. (2012) . Briefly, under isoflurane anesthesia and aseptic conditions, one end of a catheter was passed to the level of the right atrium by way of a femoral or jugular vein. The distal end of the catheter was passed subcutaneously and exited in the mid-scapular region. The catheters were flushed daily with saline and were sealed with stainless steel obturators when not in use. Monkeys wore nylon-mesh jackets (Lomir Biomedical; Toronto, Canada) at all times to protect the catheter.
Apparatus Experimental sessions were conducted in ventilated and sound-attenuating chambers that were equipped with white noise generators to mask external sounds. Within the chamber, monkeys were seated in primate chairs with a response lever mounted on the front panel (Med Associates, Inc.; Georgia, VT). Each press of the lever with a minimum downward force of approximately 0.25 N was recorded as a response. Colored lights mounted above the lever could be illuminated to serve as visual stimuli. Catheters were connected to a syringe pump (Med Associates, Inc.; Georgia, VT) located outside of the chamber. Each operation of the pump lasted 1 s and delivered 0.18 ml of vehicle or drug solution into the catheter.
Cocaine self-administration and extinction The monkeys were trained to self-administer cocaine under a second-order fixed-interval (FI), fixed-ratio (FR) schedule of i.v. drug injection similar to the schedule described by Khroyan et al. (2000) . Briefly, in the presence of a white light, completion of every 10th or 30th response (FR10 or FR30, depending on the particular monkey) during a 10 min FI resulted in a 2 s presentation of a red light. Completion of the first FR after the FI elapsed resulted in an i.v. injection of cocaine simultaneous with the onset of the red light (cocaine-paired stimulus). Each injection was followed by a 60 s time out (TO) period, during which all lights were off and responses had no scheduled consequences. If the FR requirement was not completed within 8 min following the expiration of the FI, the component ended automatically without an injection and was followed by a 60 s TO period. Daily sessions ended after completion of five cycles of the second-order schedule or a maximum of 90 min, whichever occurred first. Initially, the dose of cocaine was varied over a ten-fold or greater range to determine the dose that maintained maximum rates of responding for each monkey. The selected cocaine doses were 0.3 (N=3), 0.18 (N=4), or 0.1 mg/kg/infusion (N=3) depending upon the monkey, and these doses of cocaine were kept constant for the remainder of the study.
After establishment of stable cocaine self-administration over a period of 6 to 8 months, responding was extinguished by substituting saline for cocaine as the available solution for self administration and omitting presentations of the cocainepaired stimulus. Extinction sessions, including session and TO durations, were otherwise identical to those described above. Extinction sessions were conducted daily until responding declined and stabilized at ≤10 % of the response rate maintained during active cocaine self-administration for at least two consecutive sessions.
Reinstatement of drug seeking Tests for priming-induced reinstatement of extinguished cocaine seeking were begun once the criteria for extinction were satisfied. Reinstatement test sessions used procedures identical to those during cocaine self-administration except that only saline was available for self administration. Response-contingent presentations of the cocaine-paired stimulus were restored during reinstatement test sessions because earlier studies showed that reinstatement of cocaine-seeking behavior was greatest when cocaine priming was accompanied by restoration of the cocaine-paired stimulus (Spealman et al. 2004) . Priming injections of cocaine and saline were administered i.v. immediately before the session. Between reinstatement test sessions, one or more extinction sessions were conducted to ensure that monkeys continued to meet the extinction criteria. Between experiments with different pretreatment drugs (described below), cocaine selfadministration was re-established using the procedures described previously until responding stabilized (i.e., no systematic upward or downward trend in response rate over ≥3 consecutive sessions).
To evaluate the degree to which drug seeking was reinstated by a meaningful range of priming doses of cocaine, tests were conducted with saline and cocaine doses of 0.1-1 mg/kg. Similarly, we tested a range of doses of the 5-HT2C agonist Ro 60-0175 (0.1-1 mg/kg) and the 5-HT2C antagonist SB 242084 (0.03-0.56 mg/kg) to determine the extent to which these drugs reinstated cocaine-seeking behavior. Cocaine and SB 242084 were administered i.v. immediately before the session, followed by a saline flush to clear the catheter of residual drug solution. Ro 60-0175 was administered i.m. 30 min before the start of the session. Different doses of a particular drug were tested on different days, and each test session was separated by two or more extinction sessions. The order of testing was varied across monkeys.
Drug interaction experiments were conducted to determine the extent to which Ro 60-0175 and SB 242084 attenuated or augmented the priming effects of cocaine. Initially, a range of doses of Ro 60-0175 (0.1-1 mg/kg) or vehicle was administered as pretreatments 30 min before a maximally effective priming dose of cocaine (1 mg/kg). Based on results of this experiment, vehicle and Ro 60-0175 (1 mg/kg) then were administered as pretreatments before a full range of cocaine priming doses (vehicle, 0.1-1 mg/kg). Because Ro 60-0175 has been shown to block reinstatement induced by cocaine contextual cues (e.g., Fletcher et al. 2008) , an additional study directly compared the extent to which Ro 60-0175 attenuated cocaine priming-induced reinstatement in the presence and absence of response-contingent presentations of the cocainepaired stimulus. In this study, Ro 60-0175 (1 mg/kg) was administered as a pretreatment before i.v. priming injections of cocaine (1 mg/kg) during test sessions in which the cocaine-paired stimulus was either presented contingent on responding or was omitted entirely. Finally, SB 242084 (0.1 mg/kg) was administered as a pretreatment immediately before the administration of one of a range of priming doses of cocaine. This intermediate dose of SB 242084 was chosen for pretreatment to ensure against untoward effects, which have been reported at higher doses in squirrel monkeys (e.g., emesis and excessive scratching; Manvich et al. 2012b) .
To determine the extent to which SB 242084 might reverse the functional antagonism of cocaine by Ro 60-0175, more extensive antagonism studies were conducted with combinations of cocaine, SB 242084, and Ro 60-0175. A comparison study also was conducted with combinations of cocaine, SB 242084, and the 5-HT transport inhibitor fluoxetine. This additional study was undertaken based on the previous findings that fluoxetine, like Ro 60-0175, can significantly attenuate the effects of cocaine priming (Rüedi-Bettschen et al. 2010) . SB 242084 (0.03-0.56 mg/kg) was administered after pretreatment with either a maximally effective dose of Ro 60-0175 (1 mg/kg) or fluoxetine (5.6 mg/kg; Rüedi-Bettschen et al. 2010) followed by a maximally effective priming dose of cocaine (1 mg/kg).
Finally, because tolerance has been shown to develop rapidly with some 5-HT drugs including 5-HT2C receptor agonists (e.g., Fone et al. 1998) , we administered Ro 60-0175 or vehicle (i.m., 30 min pre-session) daily for 21 days during which time only extinction sessions were run as described above. Ro 60-0175 (or vehicle) administration commenced on day 1 of extinction. Following this period of repeated administration, we redetermined the effects of pretreatment with Ro 60-0175 on cocaine priming-induced reinstatement under identical conditions as described above (i.e., Ro 60-0175 was administered 30 min prior to a maximally effective priming dose of cocaine). To avoid potential Bceiling^or Bfloor^effects on response rate, we chose to evaluate the effects of 0.56 mg/kg Ro 60-0175, an intermediate dose that attenuated but did not completely eliminate drug-seeking induced by cocaine priming.
Behavioral observations Quantitative observational techniques (cf. Platt et al. 2000) were used to evaluate the behavioral effects of Ro 60-0175 in a subgroup of monkeys (N=4) that also had been subjects in the reinstatement studies. A range of doses of Ro 60-0175 (0.1-1 mg/kg) or vehicle was administered to the monkeys, and their behavior was assessed in the home cage, during 5-min observation periods at 30-and 120-min post injection. These observation intervals were selected to capture the start and end of a typical reinstatement session. Doses of Ro 60-0175 and vehicle were studied in random order among the monkeys. The behavior was scored by a trained observer who was not informed about the drug under study. The behavioral scoring system included 11 categories (see Table 1 ) that were scored by recording the presence or absence of each behavior in 15-s intervals during each 5-min observation period. Modified frequency scores were calculated from these data as the number of 15-s intervals in which a particular behavior was observed.
Analysis of drug effects For reinstatement studies, the rate of responding in individual monkeys was computed for each session by dividing the total number of responses by the total elapsed time (excluding responses and time during TO periods). For each experimental condition, the mean response rate±S.E.M. was calculated for the corresponding group of monkeys. All monkeys (N=10) were tested with a full range of priming doses of cocaine. Thereafter, subgroups of monkeys (N=4-8) participated in the various experiments involving Ro 60-0175, SB 242084, and fluoxetine alone and/or combined with cocaine priming.
Statistical analysis was conducted using SigmaStat 3.0. Data were analyzed by one-way or two-way repeated measures analysis of variance (ANOVA) and Bonferroni t tests to assess the differences between control conditions and test drugs. The control conditions were either vehicle priming tests for experiments in which the drugs were tested alone, or cocaine priming with vehicle pretreatment for experiments in which cocaine was combined with other drugs.
In the observation study, individual scores for each behavior were averaged over the two 5-min observation periods, as no significant differences in scores were detected between the two time points. Scores were then averaged across subjects to provide group means and analyzed by separate one-way repeated measures ANOVAs, followed by Bonferroni t tests. The α-level for all statistical tests was set at p≤0.05.
Drugs (−)-Cocaine hydrochloride was dissolved in 0.9 % saline solution. Ro 60-0175 fumarate and fluoxetine hydrochloride were dissolved in sterile water. SB 242084 dihydrochloride was dissolved in sterile water containing 20 % propylene glycol (v:v). Compounds were purchased from Tocris Cookson (Ellisville, MO) or Sigma Aldrich (St. Louis, MO). Intramuscular injection volumes were 0.1 ml/kg of body weight. 
Results
Cocaine self-administration and priming-induced reinstatement of drug seeking Self-administered cocaine maintained consistently high rates of responding in individual monkeys under the second-order schedule of i.v. drug injection, ranging from 0.5 to 1.8 responses/s in individual monkeys (group mean: 0.86±0.15 responses/s, N=10). During extinction sessions (range: 2-5 days depending on the monkey), in which saline was substituted for cocaine and the cocaine-paired stimulus was omitted, responding declined and stabilized at low rates, ranging from 0 to 0.15 responses/ s depending on the individual monkey (group mean: 0.05± 0.02 responses/s). Priming injections of cocaine (0.1-1 mg/kg) administered before test sessions in which the cocaine-paired stimulus was restored but only saline was available for selfadministration produced reliable, dose-dependent reinstatement of cocaine-seeking behavior ( Fig. 1a; F 3 ,27 =15.8, p< 0.001). Average response rates engendered by priming with 0.3 and 1 mg/kg cocaine were significantly higher than the rates obtained with vehicle (p<0.05, Bonferroni t tests) and approached response rates that were maintained by active cocaine self-administration. Priming injections of vehicle did not induce responding significantly above the level observed during extinction (point above V). When the 5-HT2C agonist Ro 60-0175 or antagonist SB 242084 were administered as priming injections, neither drug increased response rates significantly above the level obtained with vehicle priming (Fig. 1b) .
Effects of 5-HT2C ligands on cocaine priming-induced reinstatement Pretreatment with a range of doses of Ro 60-0175 before a maximally effective cocaine prime (1 mg/kg) resulted in dose-dependent and significant attenuation of cocaine reinstatement ( Fig. 2a; F 4 , 20 =8.0, p<0.001). A dose of 1 mg/kg Ro 60-0175 significantly reduced the priming effects of cocaine (p<0.05, Bonferroni t tests) by more than 75 % compared with vehicle pretreatment. In a follow-up experiment, when Ro 60-0175 (1 mg/kg) was administered before a range of cocaine priming doses, the cocaine dose-response function was significantly affected ( Fig. 2b ; main effect of Ro 60-0175: F 1, 5 =13.5, p<0.05), shifting downward and to the right. Compared to vehicle pretreatment, reinstatement induced by 0.3 and 1 mg/kg cocaine was significantly reduced by Ro 60-0175 (cocaine×Ro 60-0175 interaction: F 3, 15 = 15.7, p<0.001; p<0.05, Bonferroni t tests). Furthermore, the extent to which Ro 60-0175 attenuated cocaine priming did not differ regardless of whether the response-contingent, cocaine-paired cues were present or absent ( Fig. 2c ; main effect of Ro 60-0175: F 1, 3 =28.2, p<0.05; no significant Ro 60-0175×stimulus interaction). In contrast to effects observed with Ro 60-0175, SB 242084 did not significantly alter the priming effects of cocaine (Fig. 2d) .
In drug interaction studies, cocaine priming-induced reinstatement of drug seeking was attenuated significantly by both Ro 60-0175 (F 5, 23 =9.4, p<0.001) and fluoxetine (F 5, 15 =5.3, p<0.01); although Ro 60-0175 was more effective, suppressing cocaine priming maximally by 80 % compared to 50 % for fluoxetine (Fig. 3) . Both Ro 60-0175-and fluoxetine-induced attenuation of cocaine priming could be reversed by administration of SB 242084 (Ro 60-0175, F 5, 23 =9.4, p<0.001; Fluoxetine, F 5, 15 =5.3, p<0.01). In the case of attenuation of cocaine priming by Ro 60-0175, even the lowest dose of SB 242084 (0.03 mg/kg) returned responding toward baseline levels (e.g., levels observed with cocaine priming alone; p<0.05, Bonferroni t tests). In the case of attenuation of cocaine priming by fluoxetine, only the highest dose of SB 242084 (0.56 mg/kg) restored responding to levels observed with cocaine priming alone (p<0.05, Bonferroni t tests).
To assess the degree to which chronic administration might alter the effects of Ro 60-0175, we evaluated attenuation of cocaine priming by Ro 60-0175 both before and after 21 days of daily treatment with Ro 60-0175. A single pretreatment with again significantly reduced cocaine-induced reinstatement relative to repeated vehicle pretreatment (t 3 =10.4, p<0.002, Fig. 4b , compare BC+Ro^to BC+V^). Furthermore, after chronic administration, the extent to which Ro 60-0175 attenuated cocaine priming-induced reinstatement (approximately 43 %) was essentially unchanged from acute conditions. Thus, chronic administration neither augmented nor diminished the effectiveness of Ro 60-0175 in blunting cocaine-induced reinstatement of drug seeking.
Observable effects of Ro 60-0175 Ro 60-0175 (0.1-1 mg/kg) had no significant effect on the majority of behaviors examined including locomotion, object exploration, foraging, visual scanning, and vocalization. Ro 60-0175 also did not alter significantly resting, static, or procumbent postures. Ro 60-0175 did, however, produce a significant reduction in the self-directed behaviors scratching (F 3, 9 =5.5, p<0.05; Fig. 5 , left) and self-grooming (F 3, 9 =6.4, p<0.05; Fig. 5, right) . Post-hoc analyses revealed that scratching was significantly reduced by 0.3 and 1 mg/kg Ro 60-0175 compared to vehicle (p<0.05, Bonferroni t tests), and that self-grooming was significantly reduced by 1 mg/kg Ro 60-0175 compared to vehicle (p<0.05, Bonferroni t tests).
Discussion
Previous work has demonstrated that increasing 5-HT levels in the synapse via administration of 5-HT transport inhibitors results in attenuation of the behavioral and neurochemical effects of cocaine in laboratory animals. Less is known, however, regarding the 5-HT receptor mechanisms underlying this modulation. In the present study, both the 5-HT2C receptor agonist Ro 60-0175 and the 5-HT transport inhibitor fluoxetine attenuated the priming effects of cocaine. The cocaineattenuating effects of both drugs were reversed by the 5-HT2C antagonist SB 242084 indicating that the reduction in cocaine seeking by fluoxetine and Ro 60-0175 was due, at least in part, to specific 5-HT2C receptor-mediated agonism. Interestingly, a higher dose of SB 242084 was needed to fully reverse fluoxetine's effects compared to the effects of Ro 60-0175. The lower potency of SB 242084 to reverse the effects of fluoxetine may reflect the fact that fluoxetine's effects are mediated via multiple 5-HT receptor subtypes. For example, we and others have shown roles for both the 5-HT1A (Rüedi-Bettschen et al. 2010) and 5-HT2A (Sawyer et al. 2012 ) receptors in fluoxetine's ability to attenuate the reinstatement of drug seeking induced by cocaine priming. findings suggest that tolerance may not be an issue for the cocaine-attenuating properties of 5-HT2C agonists.
Finally, any prospective pharmacotherapy should be free from side effects that would hinder patient compliance. As noted earlier, our observation studies did not reveal any indication of sedative-like or motor-impairing effects with acute Ro 60-0175 treatment. We did, however, observe a reduction in self-directed scratching and grooming with intermediate-tohigh doses of Ro 60-0175 (i.e., 0.3 and 1 mg/kg). Increases in self-directed behaviors have been associated with anxiety and stress in nonhuman primates and have been shown to be amenable to reduction with typical anxiolytics such as alprazolam (e.g., Schino et al. 1996; Castles et al. 1999; Troisi 2002; Birkett et al. 2005) . Thus, the reduction in scratching and grooming by Ro 60-0175 may be indicative of an anxiolytic-like effect. Although speculative, this interpretation would be consistent with findings in rodents that Ro 60-0175 blocks reinstatement of drug seeking induced by the pharmacological stressor yohimbine (Fletcher et al. 2008) , produces an anxiolytic-like effect in the elevated plus maze model of anxiety (Nic Dhonnchadha et al. 2003) , and prevents stressinduced enhancement of brain 5-HT turnover and dopamine release (Pozzi et al. 2002; Mongeau et al. 2010) . From a human treatment perspective, cocaine abstinence is frequently associated with increases in anxiety, and relapse to cocaine use is often triggered by stress. Thus, medications with anxiolytic-like properties may increase the likelihood of maintaining abstinence and preventing relapse to drug selfadministration.
